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Abstract
            After implantation of a permanent pacemaker, patients may experience severe symptoms
of dyspnea, palpitations, malaise, and syncope resulting from pacemaker syndrome.  Although
pacemaker syndrome is most often ascribed to the loss of atrioventricular (A-V) synchrony,
more recent data may also implicate left ventricular dysynchrony caused by right ventricular
pacing.  Previous studies have not shown reductions in mortality or stroke with rate-modulated
dual-chamber (DDDR) pacing as compared to ventricular-based (VVI) pacing. The benefits in
A-V sequential pacing with the DDDR mode are likely mitigated by the interventricular (V-V)
dysynchrony imposed by the high percentage of ventricular pacing commonly seen in the DDDR
mode.   Programming DDDR pacemakers to encourage intrinsic A-V conduction and reduce
right ventricular pacing will likely decrease heart failure and pacemaker syndrome.  Studies are
currently ongoing to address these questions.
Keywords:  VVI  =  ventricular-based, VVIR  =  rate  modulated  ventricular-based,  A-V =
atrioventricular, V-V = interventricular, V-A = ventricular-atrial, LBBB = left bundle branch
block, LVEF = left ventricular ejection fraction, DDDR = rate modulated dual-chamber, SND =
sinus node dysfunction, AAI = single-chamber atrial, AF = atrial fibrillation, LV = left
ventricular, RV= right ventricular
Introduction
            
            Pacemaker syndrome consists of the cardiovascular signs and symptoms of heart failure
and hypotension induced by right ventricular (RV) pacing.  The reported incidence of pacemaker
syndrome likely approaches 20% in rate modulated ventricular-based (VVIR) pacing1. Over the
last three decades the understanding of pacemaker syndrome has evolved.  Initially described as
only the sequela of A-V dysynchrony, pacemaker syndrome may be highly influenced by RV-left
ventricular (LV) dysynchrony as well.  The intricate interplay of these two factors along with
autonomic and neurohormonal changes cause the compilation of symptoms known as the
pacemaker syndrome.
Pacemaker Syndrome
            Pacemaker syndrome was first described in 1969 by Mitsui et al. as a collection of
symptoms associated with right ventricular pacing2.   Since its first discovery, there have been
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many definitions of pacemaker syndrome, and the understanding of the cause of pacemaker
syndrome is still under investigation.  In a general sense, pacemaker syndrome can be defined as
the symptoms associated with right ventricular pacing relieved with the return of A-V and V-V
synchrony.
               The symptoms of pacemaker syndrome included dyspnea on exertion, paroxysmal
nocturnal dyspnea, orthopnea, hypotension, pre-syncope, and even syncope3,4,5.  Heart failure
signs include elevated neck veins, rales, and pedal edema.   Physical exam can often reveal
cannon A-waves.  This sign occurs secondary to ventricular-atrial (V-A) conduction and the
contraction of the atria against closed A-V valves.  Although relatively uncommon, syncope has
been attributed to pacemaker syndrome.   Syncope is usually associated with systolic blood
pressure declines of greater than 20 mm Hg that can occur with the onset of pacing.  Additional
symptoms attributed to pacemaker syndrome include easy fatigability, malaise, headache, and
the sensation of fullness and pulsations in the head and neck.  Pacemaker syndrome is most
severe when intact V-A conduction is present6.  The elevated venous pressures associated with
the contraction against closed A-V valves causes a vagal afferent response resulting in peripheral
vasodilation and hypotension.
Incidence
            The reported incidence of pacemaker syndrome has ranged from 2%7 to 83%8.  The wide
range of reported incidence is likely attributable to two factors.  The first is the criteria used to
define pacemaker  syndrome.   In  the  Pacemaker Selection  in the  Elderly  (PASE)  study,
pacemaker syndrome was defined as symptoms severe enough to warrant reprogramming from
ventricular to dual-chamber pacing9.   The Mode Selection Trial (MOST) investigators defined
pacemaker syndrome as occurring if either one of two different criteria occurred1.  The first
criteria was new or worsened dyspnea, orthopnea, elevated jugular venous pressure, rales, and
edema with ventricular (VA) conduction during ventricular pacing.  The second criteria was
symptoms of dizziness, weakness, presyncope, or syncope, and a >20 mm Hg reduction of
systolic blood pressure when the patient had VVIR pacing compared with atrial pacing or sinus
rhythm.   The second factor in the wide range of reported incidence of pacemaker syndrome is
the therapy used to resolve that diagnosis.   When surgical revision is required to upgrade a
patient from VVIR pacing, the incidence of pacemaker syndrome has been low.  In the Canadian
Trial of Physiologic Pacing (CTTOP), surgical revision was required for the change from VVIR
to dual chamber pacing, and the incidence of pacemaker syndrome was reported to be 2.7% at
three years10.   In other pacemaker mode trials, patients were implanted with dual chamber
devices and then either programmed to VVIR or DDDR pacing.   In these studies, patients
complaining of symptoms consistent with pacemaker syndrome could be easily upgraded to
DDDR mode by simple pacemaker reprogramming.  In the PASE and MOST studies  in which
devices could be reprogrammed from VVIR to DDDR mode,   the incidence of pacemaker
syndrome was higher than in those studies that required an invasive intervention to change
pacing mode9,11.  
A-V vs. V-V dysynchrony
            The majority of the symptoms of pacemaker syndrome are likely attributable to the
reduction in cardiac output that is associated with right ventricular pacing3,4,5.  Several studies
have demonstrated the hemodynamic superiority and increase in cardiac output of A-V
sequential pacing over ventricular pacing12.   Other studies have shown that A-V and V-V
synchrony are independent contributors to the hemodynamic ramifications of right ventricular
pacing13,14.   Right ventricular pacing with or without A-V synchrony induces a physiologic
contraction similar to that caused by left bundle branch block (LBBB).  The effects of LBBB
have been well studied.  LBBB leads to an asynchronous ventricular contraction leading to D.
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altered diastolic filling time, increase in mitral regurgitation, as well as a reduction in left
ventricular ejection fraction (LVEF)15,16,17.  Thus, the reduction in cardiac output and symptoms
associated with pacemaker syndrome are likely secondary to the loss of both A-V and V-V
synchrony that is associated with right ventricular apical pacing18.   
“Physiologic” vs. Ventricular pacing Trials
               The physiologic benefits of A-V sequential have caused DDDR pacing to become
common practice in most patients with sinus node dysfunction (SND).  The results of completed
randomized clinical trials of pacemaker mode selection have been somewhat conflicting.  
Overall, most trials have not shown reduction in heart failure, reduction in mortality, or
improvement in quality of life with A-V sequential pacing (Table 1).  
Table 1: Clinical Trials of Pacemaker Mode Selection
 
            In the first of such trials, Anderson et al. compared single-chamber atrial (AAI) with VVI
pacing in 225 patients with SND, normal A-V conduction, and a narrow QRS who had standard
pacing indications7.   The primary endpoints were frequency of atrial fibrillation (AF) and
thromboembolic events.  The original study follow-up was 3.3 years with a subsequent analysis
at 5.5 years.  Long term follow-up demonstrated persistent reduction in the primary endpoints of
AF, thromboembolic events, chronic AF, and all cause mortality in the AAI paced group.  At
longer follow-up, the VVI group had an increased incidence of heart failure, worsening
echocardiographic measurements of LV function, and increase in all-cause mortality.  These
long-term results   have not  been  reproduced by any  other  prospective,  randomized   trial
comparing solely atrial-based to ventricular-based pacing, although the pacing mode in  D.
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subsequent trials was mainly DDDR.
              In the PASE study, 407 patients older than 65 years of age, in sinus rhythm, who
required a pacemaker for bradycardia, were randomized to VVIR or DDDR pacing9.   The
primary end point was quality-of life.  Secondary endpoints included death from all causes, first
nonfatal stroke or death, first hospitalization for heart failure, development of atrial fibrillation,
and the development of pacemaker syndrome.  At quality of life evaluations at 3, 9 and 18
months, there were no differences between the two pacing modes.  There was a 26% crossover
rate due to the development of pacemaker syndrome. No differences in clinical outcomes were
observed.  There were some trends that showed benefit in clinical outcomes in the DDDR group,
especially in the subset of patients with SND, but none were of statistical significance.
            As a result of the conflicting data in the Anderson et al. trial and the PASE study, two
larger trials in pacemaker mode selection were performed.  In the Canadian Trial of Physiologic
Pacing (CTOPP) trial, 2568 patients with symptomatic bradycardia requiring pacing were
randomized to atrial-based (AAI, AAIR, DDD, or DDDR) or ventricular pacing (VVI or VVIR)
10.  AAI and AAIR combined for only 5% of the patients assigned to the atrial-based group.  The
remaining 95% in the atrial-based group were either DDD or DDDR paced.  The combined
endpoint of stroke or death due to cardiovascular causes after a 3-year follow-up was not
different between the two groups.   The secondary endpoints of AF and chronic AF were
observed less commonly in the atrial-based group.  After an eight year follow-up, there were no
significant differences in death or stroke between the two groups19.
            In the Mode Selection Trial in Sinus Node Dysfunction (MOST) study, 2020 patients
with SND received dual chamber pacemakers and were randomized to either VVIR or DDDR
pacing11. The mean follow-up was 33 months and the primary endpoints were death and nonfatal
stroke.   There were no differences in the primary endpoint between the two groups.   The
incidence of atrial fibrillation was lower with dual-chamber pacing.  Subsequent analyses of the
MOST data, has shown that the benefits of A-V sequential pacing are likely attenuated by the
ventricular pacing that occurs in the DDDR mode 20. Patients with a pre-paced QRS duration
less than 120 ms were analyzed for percentage of ventricular pacing and clinical events.  The
percentage of ventricular pacing was determined from stored pacemaker data. The percentage of
ventricular pacing was greater in the DDDR versus VVIR mode (90% vs. 58%).  The percentage
of ventricular pacing was a strong predictor of heart failure hospitalization in both pacing
modes.  The risk of AF increased linearly with percentage of ventricular pacing in both groups. 
The authors concluded that ventricular desynchronization imposed by ventricular pacing even
when A-V synchrony is preserved increases the risk of heart failure hospitalization and AF in
SND with normal baseline QRS duration.  The analyses by Sweeney et al. illustrate the fact that
DDDR and DDD pacing is not physiologic.  The pacing mode that is most physiologic is AAI or
AAIR. This fact can likely explain the discrepancies between the study by Anderson et al. and
the subsequent studies in pacemaker mode selection.  The benefit derived from A-V sequential
pacing in the CTTOP and MOST studies was likely counterbalanced by the detrimental effects
of right ventricular pacing seen in the DDDR mode.
            Several ongoing trials are looking at the benefits of reduction in RV pacing in the DDDR
mode. The first is the Danish Multicenter Randomized Study of Atrial Inhibited Versus Dual-
Chamber Pacing in Sick Sinus Syndrome (DANPACE).  This trial is comparing AAI pacing and
DDDR pacing with a short A-V delay.  The second is the Search A-V Extension for Promoting
Atrioventricular Conduction (SAVE-PACE) study.  This study will evaluate the use of search
hysteresis, a pacemaker feature that allows the extension of the A-V delay to reduce right
ventricular pacing.  The study investigators hypothesize that the reduction in RV pacing will
lead to a reduction in left ventricular remodeling and AF.
Conclusion
            Pacemaker syndrome is a common problem faced by clinicians who implant pacemakers
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and for those who take care of these patients.  The syndrome is likely caused by both the loss of
A-V and V-V synchrony imposed by right ventricular pacing.  The studies on pacemaker mode
selection have shown a high incidence of pacemaker syndrome.  Because of the high incidence
of pacemaker syndrome in VVIR-paced patients, atrial-based pacing is preferred.  
               These studies have also showed that DDDR pacing as compared to VVIR pacing
decreases the incidence of AF, but does not affect stroke or mortality.  The percentage of beats
ventricular paced in these studies in patients who received dual-chamber pacemakers is likely to
influence the incidence of pacemaker syndrome and heart failure.  The amount of ventricular
pacing in the DDDR mode is dependent on spontaneous A-V conduction and programmed A-V
delay.  Optimal programming should seek to reduce ventricular pacing.  The reduction in the
percentage of RV pacing in dual-chamber pacing modes will likely reduce the incidence of
pacemaker syndrome, heart failure, and possibly mortality.  
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